...
首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor.
【24h】

Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor.

机译:对人D2(短)多巴胺受体的配体结合和功效机制。

获取原文
获取原文并翻译 | 示例
           

摘要

Mechanisms of ligand binding and receptor activation for the human D2(short) dopamine receptor have been probed using two homologous series of monohydroxylated and dihydroxylated agonists (phenylethylamines and 2-dipropylaminotetralins). In ligand binding studies, the majority of compounds exhibited competition curves versus [3H]spiperone that were best fitted using a two site binding model. The compounds had different abilities (potencies and maximal effects) to stimulate [35S]GTPgammaS binding and to inhibit forskolin-stimulated cAMP accumulation. From the data it can be concluded that: (i) the ability of an agonist to stabilize receptor/G protein coupling can be used to predict agonist efficacy for some groups of compounds (2-dipropylaminotetralins) but not for others (phenylethylamines); (ii) the receptor may be activated by unhydroxylated compounds; (iii) single hydroxyl groups or pairs of hydroxyl groups on the agonist may contribute tobinding affinity, potency and efficacy; and (iv) for the 2-dipropylaminotetralin series two modes of agonist/receptor interaction have been identified associated with different relative efficacy.
机译:已使用两个同源系列的单羟基化和二羟基化激动剂(苯乙胺和2-二丙基氨基四氢萘酚)探索了人类D2(短)多巴胺受体的配体结合和受体激活机制。在配体结合研究中,大多数化合物相对于[3H] spiperone表现出竞争曲线,最好使用两个位点结合模型拟合。这些化合物具有不同的能力(效力和最大作用),以刺激[35S] GTPgammaS结合并抑制毛喉素刺激的cAMP积累。从数据可以得出以下结论:(i)激动剂稳定受体/ G蛋白偶联的能力可用于预测某些化合物(2-二丙基氨基四氢萘)而不是其他化合物(苯乙胺)的激动剂功效; (ii)受体可以被未羟基化的化合物激活; (iii)激动剂上的单个羟基或成对羟基可有助于结合亲和力,效力和功效; (iv)对于2-二丙基氨基四氢萘系列,已经确定了激动剂/受体相互作用的两种模式与不同的相对功效有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号